[A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]. 1985

Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi

A 69-year-old patient with advanced stomach cancer (Borrmann III) was treated with a combination chemotherapy regimen of cis-platinum administered one week after a course of PSK and FT-207. The maximum dosage of CDDP administered was gradually increased step by step from 20 mg/day to 40 mg/day every week. A remarkable decrease of tumor size was observed upon stomach x-ray and endoscopical examination. The cancer marker, serum CEA, determined by RIA also decreased from 59 ng/ml to 3.5 ng/ml. Moreover, no gastrointestinal disturbance was observed during this trial. From the results experienced, in this case, the combination therapy of PSK and FT-207 with CDDP was considered to be one of the most effective antineoplastic therapies available for stomach cancer, suppressing the gastrointestinal disturbances which are usually induced by CDDP administration alone.

UI MeSH Term Description Entries
D008297 Male Males
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
September 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
August 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
March 1984, European journal of cancer & clinical oncology,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
June 1979, The Japanese journal of surgery,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
May 1978, Nihon geka hokan. Archiv fur japanische Chirurgie,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
August 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
March 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Fukuo, and A Terashi, and Y Hayashi, and Y Yano, and J Atarashi
September 1984, British journal of obstetrics and gynaecology,
Copied contents to your clipboard!